An interventional study of Full process digital therapy intervention package in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.
Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital — 16 open to participants now, 17 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · China-Japan Friendship Hospital.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2024, is one of 13 with no phase, reaches primary completion later than 7 of the 16 other live ones, and was the 20th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →16 of the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 40–85
China-Japan Friendship Hospital · Sites in China
Ages 18–55
China-Japan Friendship Hospital · Sites in China
Ages 18–90
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2024.
This study's planned enrollment of 600 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 360 across the 13 interventional studies, 1,500 across the 11 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07097896China-Japan Friendship HospitalEndobronchial Silicone Valve for Patients With Emphysema | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by China-Japan Friendship Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project adopts a whole-process digital therapy intervention package composed of an inhalation technique assessment device, an electronic inhalant medication monitoring device and digital software to guide patients use the inhaler correctly personalizedly, record and manage the behavior data of chronic obstructive pulmonary disease (COPD) patients during the use of inhalant medication, and provide personalized reminders and feedback to patients according to the data. The purpose is to analyze whether this digital intervention scheme can reduce the number of acute exacerbations of COPD, improve the management effect of COPD, and reduce the burden of disease by improving the medication compliance of COPD patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
Behavioral: Full process digital therapy intervention package
Patients will accept regular inhaler medication direction, and equipped with electronic inhalation monitoring that can only record medication using data.
Patients will receive individualized inhalation skills guidance after being tested by inhalation capacity measuring device, and be equipped with electronic inhalation monitoring devices, which can record their medication using data, reminding patients to use the medication on time, and correct their inhalation mistake. They can also check their inhalation record on their mobile phones. Clinicians can check the record every month to assess their adherence.
severe exacerbation
Proportion of patients with severe acute exacerbation of COPD pulmonary disease during the follow-up period.
Time frame: 12 month
First Second Forced Expiratory Volume/ Forced Vital Capacity
First Second Forced Expiratory Volume/Forced Vital Capacity (FEV1/FVC) measured by pulmonomete, %
Time frame: 12 month
First Second Forced Expiratory Volume percentage of estimated
First Second Forced Expiratory Volume (FEV1) percentage of estimated measured by pulmonomete, %
Time frame: 12 month
peak expiratory flow
peak expiratory flow (PEF) measured by pulmonomete, L/min
Time frame: 12 month
COPD Assessment Test score
COPD assessment test (CAT) is an eight-item questionnaire range from 0 to 40. Higher scroe represents heavier symptom.
Time frame: 12 month
modified Medical Research Council scale
The modified Medical Research Council (mMRC) scale stands for the level of patient self-report dyspnea. 0 is the minimum and 4 is the maximum.
Time frame: 12 month
St. George's Respiratory Questionnairefor chronic obstructive pulmonary disease (SGRQ) score
the SGRQ scroe range from 0 to 100. 0 represents for the least and 100represents for the most.
Time frame: 12 month
peak inspiratory flow rate
peak inspiratory flow rate (PIFR) measured by the sensor in the study
Time frame: 12 month
mild and moderate exacerbation
Proportion of patients with mild and moderate acute exacerbation of COPD pulmonary disease during the follow-up period.
Time frame: 12 month
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Sep 2025, 14 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 14 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
China-Japan Friendship Hospital →